Core Viewpoint - Shanghai Pharmaceuticals announced the intention to publicly transfer 30% of its stake in China-U.S. Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. (hereinafter referred to as "China-U.S. Bristol-Myers Squibb") through a property rights transaction, with a minimum listing price of 1.023 billion yuan [1][4]. Group 1: Company Overview - China-U.S. Bristol-Myers Squibb, established in 1982, is a well-known Sino-U.S. joint venture pharmaceutical company with a registered capital of 18.44 million USD. The shareholding structure includes Bristol-Myers Squibb (China) Investment Co., Ltd. holding 60%, Shanghai Pharmaceuticals holding 30%, and China National Pharmaceutical Group Asset Management Co., Ltd. holding 10% [2][5]. - The company has launched nearly 30 products in China, covering prescription drugs for cardiovascular, metabolic, and antibiotic treatments, as well as over-the-counter products like pain relievers and multivitamins [2][5]. Group 2: Financial Performance - In 2016, China-U.S. Bristol-Myers Squibb achieved a historical peak with revenues of 4.724 billion yuan and a net profit of 622 million yuan. However, the company's operational performance has declined since then [2][5]. - For the year 2024, the company reported revenues of 1.795 billion yuan and a net profit of 248 million yuan. In the first three quarters of 2025, revenues further declined to 1.096 billion yuan, with a net profit of only 87.11 million yuan [2][5][7]. Group 3: Share Transfer and Market Strategy - In September 2025, it was reported that Bristol-Myers Squibb signed an agreement to sell its 60% stake in China-U.S. Bristol-Myers Squibb to an affiliate of Hillhouse Capital. This move is aimed at allowing Bristol-Myers Squibb to focus on key growth areas while leveraging local manufacturing and market advantages [3][6]. - The transfer of 30% of the stake by Shanghai Pharmaceuticals indicates a potential comprehensive adjustment in the shareholding structure of this over 40-year-old joint venture pharmaceutical company. The minimum price for the stake transfer is set at 1.023192 billion yuan, reflecting a strategic decision to maximize asset value and protect the interests of all shareholders, especially minority shareholders [3][6].

Core Viewpoint - The article discusses the significant withdrawal of multinational pharmaceutical companies from the Chinese market, highlighting a trend of strategic exits and the underlying reasons for these decisions. Group 1: Company Withdrawals - Italian pharmaceutical company Recordati announced the liquidation of its subsidiary in China, signaling a complete cessation of operations and a harsh reality for patients relying on its rare disease treatments [1] - At least seven multinational medical companies have made drastic decisions to exit the Chinese market within two years, including major players like Bristol-Myers Squibb and Sumitomo Pharma [2][3] - The average duration of these companies' presence in China was nearly 26 years, marking a complete historical cycle from entry to exit [3] Group 2: Reasons for Withdrawal - The first category of withdrawal reasons includes business failures, exemplified by Recordati and ZimVie, where high-priced rare disease drugs could not gain reimbursement support, leading to unsustainable operations [6][10] - The second category involves strategic divestitures for survival, as seen with companies like Sumitomo Pharma and Kyowa Kirin, which sold their businesses to reduce operational burdens while retaining rights to future drug developments [15][20] - The third category highlights the downsizing and restructuring of major companies like Bristol-Myers Squibb and UCB, which are shifting focus from low-margin products to high-risk, high-reward innovation drug sectors [21][24] Group 3: Market Dynamics - The traditional profit model for multinational pharmaceutical companies in China has collapsed due to price reductions from centralized procurement, with average price drops exceeding 50% and in some cases over 90% [31][32] - Local innovation has intensified competition, with domestic biotech companies rapidly developing products that challenge multinational firms, leading to a price war that many foreign companies cannot sustain [33][35] - Cultural conservatism within Japanese firms has contributed to their higher exit rates, as their slower decision-making processes hinder responsiveness to market changes [36] Group 4: Future Predictions - The trend of mid-sized multinational companies selling off their operations in China is expected to continue, with more companies likely to engage in divestitures or licensing agreements [40] - Multinational companies are anticipated to shift from selling drugs to acquiring early-stage biotech firms, reflecting a change in their operational focus in China [41] - The era of joint-venture pharmaceutical factories is coming to an end, with future production likely to be outsourced or divested, except for biologics that may still require local manufacturing [42][43]

Group 1 - Recordati's subsidiary in China, Ruikangdi, has officially exited the Chinese market, ceasing the supply of three rare disease drugs, which may disrupt treatment for patients [1][2] - The drug with the most significant impact from the exit is the innovative drug Shireza, which has no domestic generic alternatives, potentially leaving Cushing's syndrome patients without medication [1][2] - Approximately 40,000 to 50,000 patients in China suffer from Cushing's syndrome, with only about 3,000 requiring drug treatment [1] Group 2 - Ruikangdi, a small enterprise focused on rare diseases, is a subsidiary of Recordati, which operates in around 150 countries and has been involved in the rare disease sector since 1990 [2] - The direct reason for the market exit was a failure in health insurance negotiations, as two of its drugs did not make it into the 2025 health insurance directory [2] - The challenges faced by rare disease drug companies in China include high investment costs with low returns, as the development cost for a single orphan drug is approximately 260 million yuan, while the rare disease drug market in China accounts for only 3% of the global market [3] Group 3 - The Chinese rare disease patient population exceeds 20 million, with over 200,000 new patients added each year [3] - The industry is facing insufficient health insurance coverage, with 83% of rare disease drugs having annual treatment costs exceeding 300,000 yuan, and only 50% being included in health insurance [3] - Policy initiatives are being explored to address these challenges, such as the Boao Lecheng Pilot Zone allowing expedited approval for unapproved drugs and encouraging local innovation in the rare disease sector [3]

Group 1 - BMS is selling a 60% stake in its China joint venture, Shanghai BMS, to an affiliate of Hillhouse Capital, with the deal expected to close in early 2026 [1][4] - The divested assets include several products manufactured and sold exclusively in mainland China, such as Baraclude, Bufferin, and Theragran [1][4] - This divestiture is part of BMS's strategy to focus resources on core areas and optimize its business layout [1][4] Group 2 - Shanghai BMS was established in 1982 as the first Sino-American joint venture pharmaceutical company in China, predating other joint ventures like Xi'an Janssen and MSD [3] - The trend of foreign pharmaceutical companies exiting joint ventures in China is increasing, as the policy environment allows for wholly-owned operations [3][6] - Shanghai BMS has faced declining performance due to intensified competition and price reductions from centralized procurement, leading to a strategic decision to sell its business [4][6] Group 3 - In 2016, Shanghai BMS reported a record revenue of 4.72 billion yuan, but recent years have seen a decline in performance due to competition and pricing pressures [4] - The divestiture aligns with BMS's broader transformation plan, as the company reported a 2.48% year-over-year revenue decline in its latest financial report [4]